Avalo Therapeutics (AVTX) Return on Sales [ROS] (2016 - 2026)
Avalo Therapeutics' Return on Sales [ROS] came in at -33461.02% for Q4 2025, down 26528.20 percentage points from -6932.81% a year earlier and down 18383.01 percentage points from the prior quarter.
Powered by 
Analysis
Avalo Therapeutics (AVTX) Return on Sales [ROS] (2016 - 2026) Analysis & Trends
For FY2025, Avalo Therapeutics' Return on Sales [ROS] was -123601.69%, down 108066.09 percentage points from FY2024.
- Return on Sales [ROS] has declined in each of the last three years, with a five-year change of -122514.32 percentage points (FY2020 to FY2025).
- Going back by year, Return on Sales [ROS] was -15535.60% in FY2024 (-14114.03 pp), -1421.57% in FY2023 (-1214.16 pp), -207.41% in FY2022 (+1314.15 pp) and -1521.56% in FY2021 (-434.19 pp).
- The Q4 2025 figure represents the lowest quarterly Return on Sales [ROS] in data going back to Q3 2016.
- The fastest year-over-year change in Return on Sales [ROS] over five years came in Q4 2022 (a gain of 7214.00 percentage points), and the weakest in Q4 2025 (a drop of 26528.20 percentage points).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROS (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,348.13 Bn | 1,321.74 Bn | 20.46 Bn | 34.46% |
| 2 | Johnson & Johnson | 675.90 Bn | 595.76 Bn | 17.30 Bn | 24.35% |
| 3 | AbbVie | 519.45 Bn | 487.50 Bn | 13.12 Bn | 36.01% |
| 4 | Merck | 364.95 Bn | 327.95 Bn | 13.19 Bn | 30.74% |
| 5 | Novartis Ag | 311.58 Bn | 285.16 Bn | - | - |
| 6 | Astrazeneca | 289.34 Bn | 262.94 Bn | 13.26 Bn | 29.12% |
| 7 | Amgen | 251.64 Bn | 203.30 Bn | 7.58 Bn | 35.79% |
| 8 | Gilead Sciences | 212.05 Bn | 187.07 Bn | 6.73 Bn | 41.71% |
| 9 | Pfizer | 167.35 Bn | 115.00 Bn | 12.56 Bn | 32.98% |
| 10 | Avalo Therapeutics | 386.09 Mn | -587.48 Mn | - | -550.65% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2026 | -550.65% |
| Jun 30, 2026 | -1,141.51% |
| Mar 31, 2026 | -2,602.86% |
| Dec 31, 2025 | -33,461.02% |
| Sep 30, 2025 | -2,728.52% |
| Jun 30, 2025 | -1,760.80% |
| Mar 31, 2025 | -1,277.79% |
| Dec 31, 2024 | -6,932.81% |
| Sep 30, 2024 | -5,165.06% |
| Jun 30, 2024 | -6,660.47% |
| Mar 31, 2024 | -3,539.66% |
| Dec 31, 2023 | -1,341.16% |
| Sep 30, 2023 | -1,588.98% |
| Jun 30, 2023 | -1,111.98% |
| Mar 31, 2023 | -1,850.95% |
| Dec 31, 2022 | -988.28% |
| Sep 30, 2022 | 27.39% |
| Jun 30, 2022 | -1,145.01% |
| Mar 31, 2022 | -1,777.75% |
| Dec 31, 2021 | -8,202.28% |
API Access
Avalo Therapeutics Return on Sales [ROS] API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=return-on-sales-%5Bros%5D&ticker=AVTX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "return-on-sales-[ros]", "ticker": "AVTX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=return-on-sales-%5Bros%5D&ticker=AVTX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();